Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.


Results 21-25 of 25 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2013Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLBranford, S.; Yeung, D.; Ross, D.; Prime, J.; Field, C.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Sullivan, B.; Briggs, N.; Hertzberg, M.; Seymour, J.; Reynolds, J.; Hughes, T.
2013Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyRoss, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Yeung, D.; Dang, P.; Goyne, J.; Slader, C.; Filshie, R.; Mills, A.; Vaz de Melo, J.; White, D.; Grigg, A.; Hughes, T.
2014Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineBranford, S.; Yeung, D.; Parker, W.; Roberts, N.; Purins, L.; Braley, J.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Donaldson, Z.; Leong, M.; Fletcher, L.; Seymour, J.; Grigg, A.; Ross, D.; Hughes, T.
2019Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remissionShanmuganathan, N.; Braley, J.; Yong, A.; Hiwase, D.; Yeung, D.; Ross, D.; Hughes, T.; Branford, S.
2019Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remissionPagani, I.; Dang, P.; Saunders, V.; Grose, R.; Shanmuganathan, N.; Kok, C.; Carne, L.; Rwodzi, Z.; Watts, S.; McLean, J.; Braley, J.; Altamura, H.; Yeung, D.; Branford, S.; Yong, A.; White, D.; Hughes, T.; Ross, D.